Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
Executives used to lean toward European regulators launching their products in that region. But after a decade of change, they now see the U.S. as a better option. While the FDA gets kudos, the other issue remains challenging: reimbursement.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pharma companies moved fast in 2020 to tackle Covid-19 and to address longstanding issues of racial equity, the CEOS of BD and Sanofi said in a session at the J.P. Morgan Healthcare Conference. The challenge lies in keeping the momentum going in 2021.
After a banner year for digital health, characterized by record adoption and investment, what will come next? Partners with Boston Consulting Group’s Digital Ventures shared their predictions for 2021.
With the tax reform bill that recently passed and the dramatic rate-cut for overseas cash being repatriated to 14.5 percent from 35 percent, it's no surprise that M&A deals will abound.
Boston Consulting Group put together a slick series of infographics that track the evolution of robotics since the 1950s. The graphs show that robotics didn’t really make waves in the life sciences until 2000 and later – but today, robotic surgery is rapidly gaining a place in the medical community. All signs point toward that evolution chart […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.